An observational study to identify causative factors for not using hydroxychloroquine in systemic lupus erythematosus
Open Access
- 2 April 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-6
Abstract
Hydroxychloroquine (HCQ) use is indicated for patients with systemic lupus erythematosus (SLE). Nevertheless, reports discussing the reasons for not prescribing HCQ are limited. We identified the factors that interfere with HCQ use in patients with SLE. This observational, single-center study included data from 265 patients with SLE in 2019. The patients were categorized into groups with and without a history of HCQ use. Between these groups, clinical characteristics were compared using univariate analysis and logistic regression models. Among the 265 patients, 133 (50.2%) had a history of HCQ use. Univariate analysis identified older age; longer disease duration; lower prednisolone dose, clinical SLE disease activity index 2000, and estimated glomerular filtration rate; higher C3 level; and lower anti-double-stranded DNA antibody concentration as HCQ non-use-related variables. Logistic regression models identified a positive association between HCQ non-use and longer disease duration (odds ratio [OR] 1.08), prednisolone dose ≤ 7.5 mg/day (OR 4.03), C3 level ≥ 73 mg/dL (OR 2.15), and attending physician having graduated > 10 years prior (OR 3.19). In conclusion, a longer disease duration, lower prednisolone dose, higher C3 level, and longer time since attending physicians’ graduation correlated with HCQ non-use. Physicians and patients should be educated to facilitate HCQ use despite these factors.Keywords
All Related Versions
This publication has 40 references indexed in Scilit:
- Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double‐Blind, Randomized, Parallel‐Group TrialArthritis & Rheumatology, 2017
- Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus ErythematosusArthritis & Rheumatology, 2015
- The Risk of Toxic Retinopathy in Patients on Long-term Hydroxychloroquine TherapyJAMA Ophthalmology, 2014
- Antimalarial treatment may have a time‐dependent effect on lupus survival: Data from a multinational Latin American inception cohortArthritis & Rheumatism, 2010
- The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosusArthritis & Rheumatism, 2010
- Hydroxychloroquine and Risk of Diabetes in Patients With Rheumatoid ArthritisJAMA, 2007
- Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrualArthritis & Rheumatism, 2005
- Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosusArthritis & Rheumatism, 2001
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- Anti‐dsdna and complement profiles as prognostic guides in systemic lupus erythematosusArthritis & Rheumatism, 1979